中金发表研究报告指，信达生物(01801.HK) 首季产品收入逾24亿元人民币，按年保持40%以上增长，符合预期。此外，集团预告将会在2025 ASCO年会读出多个重磅数据，包括七项口头报告。
该行相信，信达生物商业化产品不断丰富，预计今年收入将维持第一季的强劲增长趋势，维持集团今明两年的纯利预测4.72亿及12.98亿元人民币，重申“跑赢行业”评级。该行考虑到集团IBI363 PoC数据成熟及ADC管线进展，可望解锁更多全球商业化空间，将目标价上调12.2%至66港元。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-07 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.